TransCode Therapeutics, Inc. develops RNA and immuno-oncology therapeutics for high-risk and advanced cancers. News about RNAZ centers on its lead candidate TTX-MC138, an antagomiR targeting microRNA-10b, along with preclinical publications, IND-related clinical updates, research collaborations and sponsored research tied to RNA-targeted oncology.
Company updates also cover additions to its early-stage oncology pipeline, including adenovirus-based oncolytic immunotherapy candidates UIO-524, UIO-525 and UIO-526, as well as governance changes involving its board and scientific advisory structure. Capital-structure announcements, material agreements and operating or financial results are recurring disclosure themes for this clinical-stage biotechnology issuer.
TransCode Therapeutics (NASDAQ: RNAZ) has received FDA authorization to commence its First-in-Human (FIH) Phase 0 clinical trial for TTX-MC138, targeting advanced solid tumors in up to 12 cancer patients. TTX-MC138 aims to inhibit microRNA-10b, a key player in metastasis. The trial will assess the delivery of the therapeutic to metastatic lesions and gather crucial pharmacokinetic data. Preclinical results indicate TTX-MC138's potential effectiveness in various cancers, demonstrating complete responses in animal studies. This marks a significant advancement for TransCode as a clinical-stage oncology company.
TransCode Therapeutics (NASDAQ: RNAZ) has withdrawn its Registration Statement on Form S-1, initially filed on November 28, 2022, due to unfavorable market conditions. The Company believes these conditions do not align with the best interests of its stockholders for a public offering. TransCode focuses on RNA-based cancer treatments, aiming to improve patient outcomes with its therapeutic candidates targeting various tumor types. Their lead candidate, TTX-MC138, aims to treat metastatic cancer, a leading cause of cancer deaths worldwide.
TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an exploratory eIND application to the FDA for a First-in-Human Phase 0 clinical trial of TTX-MC138, targeting advanced solid tumors. This therapeutic aims to inhibit microRNA-10b, a key player in metastasis. The trial will involve up to 12 patients to assess the safety and pharmacokinetics of TTX-MC138. Successful results could pave the way for further clinical trials and potential treatments for aggressive cancers like breast and pancreatic cancer.
TransCode Therapeutics (NASDAQ: RNAZ) reported Q3 2022 financial results, highlighting significant advancements in its RNA oncology pipeline. The company remains on schedule to submit an exploratory IND application for a Phase 0 trial involving TTX-MC138 in advanced solid tumors. Recently granted orphan drug designation for TTX-siPDL1 for pancreatic cancer emphasizes its focus on high-need areas. Financially, cash reserves decreased to $8.8 million, while R&D expenses surged to $3 million, reflecting ongoing investment in therapeutic development. The company expects funding will last through Q1 2023.
TransCode Therapeutics (RNAZ) announced positive preclinical results for its immunotherapy candidate TTX-siPDL1 in treating pancreatic adenocarcinoma. After two weekly treatments with TTX-siPDL1 and gemcitabine, tumor volumes were significantly reduced, with 75% of treated animals surviving compared to 25% for gemcitabine alone. The study demonstrated effective PD-L1 inhibition and immune activation. CEO Michael Dudley highlighted the platform's capability to overcome challenges in RNA delivery within tumors, marking a significant opportunity for the company.
TransCode Therapeutics (Nasdaq: RNAZ) has announced its participation in the Sidoti Virtual Investor Conference on November 9-10, 2022. CEO Michael Dudley will present the company's advancements in RNA-based therapies targeting metastatic cancer, including its lead candidate TTX-MC138, which is entering first-in-human clinical trials. The presentation is scheduled for 2:30 pm ET on November 9 and will be available via webcast. TransCode aims to innovate cancer treatment through RNA therapeutics and has developed multiple candidates addressing various tumors.
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) reported positive preclinical results for its lead candidate TTX-MC138 in treating pancreatic adenocarcinoma. The murine study showed a 40% complete response rate with treated mice and a successful pharmacodynamic response demonstrated by down-regulation of microRNA-10b. Further studies are underway to optimize dosing. TTX-MC138 has previously shown efficacy in breast cancer models, and the company plans to file an exploratory Investigational New Drug application for a Phase 0 clinical trial later this year.
TransCode Therapeutics (Nasdaq: RNAZ) announced the publication of a case study in Frontiers in Oncology regarding its lead therapeutic candidate, TTX-MC138. The study involved a feline patient with spontaneous metastatic breast cancer that had previously failed multiple chemotherapy rounds. TTX-MC138 demonstrated effective delivery to tumor cells via MRI and fluorescence microscopy. The patient experienced tolerable treatment and survived five months longer than expected, suggesting TTX-MC138's potential in advancing clinical trials for human metastatic cancer treatment.
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) announced its participation at the Chardan 6th Annual Genetic Medicines Conference on October 3-4, 2022. CEO Michael Dudley will present the company's RNA-based innovations aimed at enhancing cancer treatment, including the lead candidate TTX-MC138 focused on metastatic disease, set to enter clinical trials this year. The presentation is scheduled for 1:00 pm ET on October 3 and will be available for live streaming.
TransCode Therapeutics (RNAZ) announced the appointment of Frank J. Slack, PhD, a leader in small noncoding RNA research, to its advisory board. His expertise is anticipated to bolster the company’s mission as it enters clinical development phases with its lead product, TTX-MC138, aimed at treating metastatic cancers responsible for approximately 90% of cancer deaths globally. Slack's background includes pioneering studies on microRNAs, which are crucial for cancer targeting. This strategic addition aligns with upcoming first-in-human studies intended to advance TransCode's innovative RNA therapeutic approaches.